source
- Pfizer ends Trillium-related development as R&D spend jumpsPfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company…Endpoints · 3mo ago↗ source
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- Microbiome startup raises $48M for immunotherapy and malnutrition treatmentsScientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied th…Endpoints